Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir
 PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with
 pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare
 these results to non-amyloid diseased controls.
Patients with pathologically proven amyloidosis involving the peripheral nervous system will
 undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A
 control arm comprised of patients with pathologically-confirmed non-amyloid causes of
 peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be
 reviewed for peripheral nerve uptake.
Inclusion Criteria:

 -  Adults: 18-100

 -  Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed
 non-amyloid causes of peripheral neuropathy

 Exclusion Criteria:

 -  Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)

 -  Claustrophobia

 -  BMI over 38